ES2985416T3 - Nuevos compuestos potentes y selectivos como moduladores del receptor de serotonina 1B - Google Patents

Info

Publication number

ES2985416T3

ES2985416T3 ES21789678T ES21789678T ES2985416T3 ES 2985416 T3 ES2985416 T3 ES 2985416T3 ES 21789678 T ES21789678 T ES 21789678T ES 21789678 T ES21789678 T ES 21789678T ES 2985416 T3 ES2985416 T3 ES 2985416T3

Authority

ES

Spain

Prior art keywords

methyl

oxadiazol

ethoxy

dimethylamino

phenyl

Prior art date

2020-10-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 83
• 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 title claims abstract description 31
• 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 title claims description 32
• 230000003389 potentiating effect Effects 0.000 title description 5
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
• 238000011282 treatment Methods 0.000 claims abstract description 23
• 201000011510 cancer Diseases 0.000 claims abstract description 20
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
• 201000010099 disease Diseases 0.000 claims abstract description 13
• 208000023504 respiratory system disease Diseases 0.000 claims abstract description 13
• 208000019423 liver disease Diseases 0.000 claims abstract description 11
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 68
• 235000005152 nicotinamide Nutrition 0.000 claims description 34
• 239000011570 nicotinamide Substances 0.000 claims description 34
• 229960003966 nicotinamide Drugs 0.000 claims description 34
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 30
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 30
• KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 18
• 150000003839 salts Chemical class 0.000 claims description 17
• 125000005843 halogen group Chemical group 0.000 claims description 16
• 239000003814 drug Substances 0.000 claims description 14
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
• 239000013066 combination product Substances 0.000 claims description 8
• 229940127555 combination product Drugs 0.000 claims description 8
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
• 206010066476 Haematological malignancy Diseases 0.000 claims description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
• 230000008485 antagonism Effects 0.000 claims description 6
• 229910052757 nitrogen Inorganic materials 0.000 claims description 6
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
• 230000001575 pathological effect Effects 0.000 claims description 5
• 125000001424 substituent group Chemical group 0.000 claims description 5
• 229940124597 therapeutic agent Drugs 0.000 claims description 5
• 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
• WKRMNNWLWBWNLA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 WKRMNNWLWBWNLA-UHFFFAOYSA-N 0.000 claims description 4
• IDMJYSVBSMXIDI-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 IDMJYSVBSMXIDI-UHFFFAOYSA-N 0.000 claims description 4
• DMBQZOISSRPCIC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 DMBQZOISSRPCIC-UHFFFAOYSA-N 0.000 claims description 4
• NEYFLJXXSDPBCH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 NEYFLJXXSDPBCH-UHFFFAOYSA-N 0.000 claims description 4
• UCQLYQBGXGOQCG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 UCQLYQBGXGOQCG-UHFFFAOYSA-N 0.000 claims description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 229910052731 fluorine Inorganic materials 0.000 claims description 4
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
• HGYLTZHADHYQNA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 HGYLTZHADHYQNA-UHFFFAOYSA-N 0.000 claims description 3
• KDDXXBYALZGLHX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 KDDXXBYALZGLHX-UHFFFAOYSA-N 0.000 claims description 3
• KCWVWVUHPWLROW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 KCWVWVUHPWLROW-UHFFFAOYSA-N 0.000 claims description 3
• RNORLAMEMJTVPV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 RNORLAMEMJTVPV-UHFFFAOYSA-N 0.000 claims description 3
• BTPQOZLQYPEILQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 BTPQOZLQYPEILQ-UHFFFAOYSA-N 0.000 claims description 3
• YMVNHGZYFZFHMS-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 YMVNHGZYFZFHMS-UHFFFAOYSA-N 0.000 claims description 3
• VSKLNOAHLUAKHL-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 VSKLNOAHLUAKHL-UHFFFAOYSA-N 0.000 claims description 3
• UUDUCQTYLISIAL-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 UUDUCQTYLISIAL-UHFFFAOYSA-N 0.000 claims description 3
• ZVKGETGOELYILX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 ZVKGETGOELYILX-UHFFFAOYSA-N 0.000 claims description 3
• 125000003277 amino group Chemical group 0.000 claims description 3
• 239000002246 antineoplastic agent Substances 0.000 claims description 3
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
• 125000005842 heteroatom Chemical group 0.000 claims description 3
• 239000002955 immunomodulating agent Substances 0.000 claims description 3
• 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 2
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
• AKLZTLIDPGPARM-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 AKLZTLIDPGPARM-UHFFFAOYSA-N 0.000 claims description 2
• LUFNCYOYMOMMNR-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 LUFNCYOYMOMMNR-UHFFFAOYSA-N 0.000 claims description 2
• QJBIDOKVAKPOCN-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 QJBIDOKVAKPOCN-UHFFFAOYSA-N 0.000 claims description 2
• HYXPMSNQGXPFDG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HYXPMSNQGXPFDG-UHFFFAOYSA-N 0.000 claims description 2
• XEXBGLIFZLBHJQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 XEXBGLIFZLBHJQ-UHFFFAOYSA-N 0.000 claims description 2
• ARTHJZBQVIILKI-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 ARTHJZBQVIILKI-UHFFFAOYSA-N 0.000 claims description 2
• VSKSGHUYVPALCB-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 VSKSGHUYVPALCB-UHFFFAOYSA-N 0.000 claims description 2
• HNZMGCCCOSRCSD-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HNZMGCCCOSRCSD-UHFFFAOYSA-N 0.000 claims description 2
• YKEMKZJDHOXQNC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 YKEMKZJDHOXQNC-UHFFFAOYSA-N 0.000 claims description 2
• HVTSQRXEZRBMJU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HVTSQRXEZRBMJU-UHFFFAOYSA-N 0.000 claims description 2
• TXEWRHMDULAEOH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 TXEWRHMDULAEOH-UHFFFAOYSA-N 0.000 claims description 2
• KUFZCASWZPHPGY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 KUFZCASWZPHPGY-UHFFFAOYSA-N 0.000 claims description 2
• VSOMIPBUJQCXGL-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 VSOMIPBUJQCXGL-UHFFFAOYSA-N 0.000 claims description 2
• QNUWHCPAJAJDOA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 QNUWHCPAJAJDOA-UHFFFAOYSA-N 0.000 claims description 2
• PJFQHYDSGISEIW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 PJFQHYDSGISEIW-UHFFFAOYSA-N 0.000 claims description 2
• GPWJQOWHTBGDNK-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 GPWJQOWHTBGDNK-UHFFFAOYSA-N 0.000 claims description 2
• MDFDNENUWXMCFV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 MDFDNENUWXMCFV-UHFFFAOYSA-N 0.000 claims description 2
• RHAPZGCORGTSST-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 RHAPZGCORGTSST-UHFFFAOYSA-N 0.000 claims description 2
• QLSOTVJXMCZKEB-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 QLSOTVJXMCZKEB-UHFFFAOYSA-N 0.000 claims description 2
• DETSYTXQXQIYPO-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 DETSYTXQXQIYPO-UHFFFAOYSA-N 0.000 claims description 2
• XCQDOZFRSBWIGG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 XCQDOZFRSBWIGG-UHFFFAOYSA-N 0.000 claims description 2
• CIHKXLZQVICQEW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 CIHKXLZQVICQEW-UHFFFAOYSA-N 0.000 claims description 2
• JLZHEEGMMGGWRU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 JLZHEEGMMGGWRU-UHFFFAOYSA-N 0.000 claims description 2
• TXTMHWUUHFAVQW-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 TXTMHWUUHFAVQW-UHFFFAOYSA-N 0.000 claims description 2
• GOLFEXPALIXFKJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 GOLFEXPALIXFKJ-UHFFFAOYSA-N 0.000 claims description 2
• QVWABOCPMMJQAV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 QVWABOCPMMJQAV-UHFFFAOYSA-N 0.000 claims description 2
• NDGORFKNJAVUQY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 NDGORFKNJAVUQY-UHFFFAOYSA-N 0.000 claims description 2
• AKQJAWAIIXUYPX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 AKQJAWAIIXUYPX-UHFFFAOYSA-N 0.000 claims description 2
• GIULCICYOABOEC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 GIULCICYOABOEC-UHFFFAOYSA-N 0.000 claims description 2
• UMEFGSAZBMCBCO-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 UMEFGSAZBMCBCO-UHFFFAOYSA-N 0.000 claims description 2
• ZVPYLANNZHZZPY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 ZVPYLANNZHZZPY-UHFFFAOYSA-N 0.000 claims description 2
• JABJCDSHLSFVLS-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 JABJCDSHLSFVLS-UHFFFAOYSA-N 0.000 claims description 2
• NGHAHNCWSQRVBO-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 NGHAHNCWSQRVBO-UHFFFAOYSA-N 0.000 claims description 2
• ILAOTZUJBKKNCV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 ILAOTZUJBKKNCV-UHFFFAOYSA-N 0.000 claims description 2
• IYMMRMDCBUSLDQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 IYMMRMDCBUSLDQ-UHFFFAOYSA-N 0.000 claims description 2
• BVFPGEQMCOESHQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 BVFPGEQMCOESHQ-UHFFFAOYSA-N 0.000 claims description 2
• DTVDYOBOXNJMPK-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 DTVDYOBOXNJMPK-UHFFFAOYSA-N 0.000 claims description 2
• ZKHDTUWYLCRTGZ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 ZKHDTUWYLCRTGZ-UHFFFAOYSA-N 0.000 claims description 2
• UMQJRNKSLUJLDJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 UMQJRNKSLUJLDJ-UHFFFAOYSA-N 0.000 claims description 2
• WXUWBWLQGJTZNF-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 WXUWBWLQGJTZNF-UHFFFAOYSA-N 0.000 claims description 2
• XHPASMPECUATQY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 XHPASMPECUATQY-UHFFFAOYSA-N 0.000 claims description 2
• YSAMJBGGJXUMKQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 YSAMJBGGJXUMKQ-UHFFFAOYSA-N 0.000 claims description 2
• BYGULHUHQDKUIP-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2Br)=O)=NO1 BYGULHUHQDKUIP-UHFFFAOYSA-N 0.000 claims description 2
• SASAFFCTHHUDNM-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 SASAFFCTHHUDNM-UHFFFAOYSA-N 0.000 claims description 2
• HYCLRLSNZCRQFK-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HYCLRLSNZCRQFK-UHFFFAOYSA-N 0.000 claims description 2
• WJJBUQFGQHDMLJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 WJJBUQFGQHDMLJ-UHFFFAOYSA-N 0.000 claims description 2
• USUHEGLDPFIFEX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 USUHEGLDPFIFEX-UHFFFAOYSA-N 0.000 claims description 2
• RQNIIWCZOYPGIJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 RQNIIWCZOYPGIJ-UHFFFAOYSA-N 0.000 claims description 2
• QVLKWTBCGMUHIH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=CC=C2C(NC(C=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 QVLKWTBCGMUHIH-UHFFFAOYSA-N 0.000 claims description 2
• BUYJOJXFBURCJZ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 BUYJOJXFBURCJZ-UHFFFAOYSA-N 0.000 claims description 2
• PVISRTSBCRPJAU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 PVISRTSBCRPJAU-UHFFFAOYSA-N 0.000 claims description 2
• LHVHHPJEZOLECI-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 LHVHHPJEZOLECI-UHFFFAOYSA-N 0.000 claims description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
• 229940044683 chemotherapy drug Drugs 0.000 claims description 2
• 229960004397 cyclophosphamide Drugs 0.000 claims description 2
• 229960000684 cytarabine Drugs 0.000 claims description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
• 229960000975 daunorubicin Drugs 0.000 claims description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
• 229960003957 dexamethasone Drugs 0.000 claims description 2
• 229950009791 durvalumab Drugs 0.000 claims description 2
• 125000001153 fluoro group Chemical group F* 0.000 claims description 2
• 229960005386 ipilimumab Drugs 0.000 claims description 2
• 229960001428 mercaptopurine Drugs 0.000 claims description 2
• 229960000485 methotrexate Drugs 0.000 claims description 2
• IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims description 2
• 229960000801 nelarabine Drugs 0.000 claims description 2
• 229960003301 nivolumab Drugs 0.000 claims description 2
• 229960002621 pembrolizumab Drugs 0.000 claims description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
• 229960004618 prednisone Drugs 0.000 claims description 2
• 229950007217 tremelimumab Drugs 0.000 claims description 2
• 229960004528 vincristine Drugs 0.000 claims description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• CWDGORUDBCIMMR-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2Br)=O)=NO1 CWDGORUDBCIMMR-UHFFFAOYSA-N 0.000 claims 1
• NKAZJDQVTVOZIE-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 NKAZJDQVTVOZIE-UHFFFAOYSA-N 0.000 claims 1
• HXVKEOJABWEOCA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 HXVKEOJABWEOCA-UHFFFAOYSA-N 0.000 claims 1
• FVWHKKVWTBOKBV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(NC(N=C2OCCN(C)C)=NC=C2C#N)=O)=NO1 FVWHKKVWTBOKBV-UHFFFAOYSA-N 0.000 claims 1
• OPNRWYVUOUFNTF-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 OPNRWYVUOUFNTF-UHFFFAOYSA-N 0.000 claims 1
• LZASDPRDDDIIBM-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(N=C2)=CC=C2NC(C(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 LZASDPRDDDIIBM-UHFFFAOYSA-N 0.000 claims 1
• YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract description 20
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract description 19
• 230000001404 mediated effect Effects 0.000 abstract description 3
• 201000005787 hematologic cancer Diseases 0.000 abstract description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract description 2
• 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 302
• 238000005160 1H NMR spectroscopy Methods 0.000 description 151
• 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 148
• 239000000543 intermediate Substances 0.000 description 115
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
• 238000000034 method Methods 0.000 description 73
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 70
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
• 239000002243 precursor Substances 0.000 description 48
• 239000007858 starting material Substances 0.000 description 48
• 235000019439 ethyl acetate Nutrition 0.000 description 43
• 239000013067 intermediate product Substances 0.000 description 42
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
• 239000000243 solution Substances 0.000 description 38
• 239000007787 solid Substances 0.000 description 36
• 238000006243 chemical reaction Methods 0.000 description 35
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
• 239000011541 reaction mixture Substances 0.000 description 34
• 239000000203 mixture Substances 0.000 description 33
• 210000004027 cell Anatomy 0.000 description 30
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
• 229940076279 serotonin Drugs 0.000 description 26
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
• 239000012074 organic phase Substances 0.000 description 23
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
• -1 hydrocarbon radicals Chemical class 0.000 description 22
• 239000000047 product Substances 0.000 description 22
• 229910052938 sodium sulfate Inorganic materials 0.000 description 22
• 235000011152 sodium sulphate Nutrition 0.000 description 22
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
• 238000004587 chromatography analysis Methods 0.000 description 16
• 238000000746 purification Methods 0.000 description 15
• 102000005962 receptors Human genes 0.000 description 14
• 108020003175 receptors Proteins 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 13
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
• 239000005557 antagonist Substances 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 210000003169 central nervous system Anatomy 0.000 description 13
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
• 239000007832 Na2SO4 Substances 0.000 description 12
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 101150017422 HTR1 gene Proteins 0.000 description 11
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
• 150000001412 amines Chemical class 0.000 description 11
• 239000012043 crude product Substances 0.000 description 11
• 239000012071 phase Substances 0.000 description 11
• 101100024116 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MPT5 gene Proteins 0.000 description 10
• 239000012267 brine Substances 0.000 description 10
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 9
• GKGKBZYMDILCOF-UHFFFAOYSA-N SB 224289 hydrochloride Chemical compound Cl.C1CN(C)CCC11C2=CC(N(C(=O)C=3C=CC(=CC=3)C=3C(=CC(=CC=3)C=3N=C(C)ON=3)C)CC3)=C3C=C2OC1 GKGKBZYMDILCOF-UHFFFAOYSA-N 0.000 description 9
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
• 238000003818 flash chromatography Methods 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 8
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 230000000875 corresponding effect Effects 0.000 description 8
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 8
• YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 7
• 108700012813 7-aminoactinomycin D Proteins 0.000 description 7
• 239000007821 HATU Substances 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 229910000024 caesium carbonate Inorganic materials 0.000 description 7
• 238000010586 diagram Methods 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 210000002569 neuron Anatomy 0.000 description 7
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
• 235000019270 ammonium chloride Nutrition 0.000 description 6
• 235000010290 biphenyl Nutrition 0.000 description 6
• QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
• 230000035515 penetration Effects 0.000 description 6
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
• CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 5
• 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 5
• 101000724725 Homo sapiens 5-hydroxytryptamine receptor 1B Proteins 0.000 description 5
• 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 5
• 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 5
• 206010046798 Uterine leiomyoma Diseases 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 125000000217 alkyl group Chemical group 0.000 description 5
• 150000001450 anions Chemical class 0.000 description 5
• 239000008346 aqueous phase Substances 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 230000000694 effects Effects 0.000 description 5
• 201000010260 leiomyoma Diseases 0.000 description 5
• 150000003254 radicals Chemical class 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 230000000862 serotonergic effect Effects 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 201000007954 uterine fibroid Diseases 0.000 description 5
• 239000011701 zinc Substances 0.000 description 5
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
• PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 4
• LUPMVIMQIVHFCV-UHFFFAOYSA-N 2-(dimethylamino)ethyl methanesulfonate Chemical compound CN(C)CCOS(C)(=O)=O LUPMVIMQIVHFCV-UHFFFAOYSA-N 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• POESQIHWIIWNJL-UHFFFAOYSA-N 4-amino-3-bromobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1Br POESQIHWIIWNJL-UHFFFAOYSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
• YJGNWQSJYGGHQR-UHFFFAOYSA-N CC1(C)OB(C(C=C2)=C(C3CC3)C=C2C2=NOC(C)=N2)OC1(C)C Chemical compound CC1(C)OB(C(C=C2)=C(C3CC3)C=C2C2=NOC(C)=N2)OC1(C)C YJGNWQSJYGGHQR-UHFFFAOYSA-N 0.000 description 4
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 4
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 4
• 229960004046 apomorphine Drugs 0.000 description 4
• 230000008499 blood brain barrier function Effects 0.000 description 4
• 210000001218 blood-brain barrier Anatomy 0.000 description 4
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
• 150000001735 carboxylic acids Chemical class 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 238000004440 column chromatography Methods 0.000 description 4
• 230000009137 competitive binding Effects 0.000 description 4
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
• 230000001472 cytotoxic effect Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000012091 fetal bovine serum Substances 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 239000002858 neurotransmitter agent Substances 0.000 description 4
• 235000001968 nicotinic acid Nutrition 0.000 description 4
• 239000011664 nicotinic acid Substances 0.000 description 4
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
• 229910052763 palladium Inorganic materials 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 239000002287 radioligand Substances 0.000 description 4
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
• 235000017557 sodium bicarbonate Nutrition 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
• QLAUMSHAQJMZPX-UHFFFAOYSA-N 4-bromo-3-[2-(dimethylamino)ethoxy]aniline Chemical compound CN(C)CCOC1=CC(N)=CC=C1Br QLAUMSHAQJMZPX-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• 206010000830 Acute leukaemia Diseases 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 101150050738 HTR1B gene Proteins 0.000 description 3
• RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 3
• 206010060862 Prostate cancer Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 208000036676 acute undifferentiated leukemia Diseases 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
• 125000005620 boronic acid group Chemical class 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 239000003480 eluent Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• VDEARWYDVSYTNZ-UHFFFAOYSA-N methyl 4-cyano-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(C#N)C(O)=C1 VDEARWYDVSYTNZ-UHFFFAOYSA-N 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• JPBMDMNORXKGHZ-UHFFFAOYSA-N n-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]benzamide;hydrochloride Chemical compound Cl.C1=C(OCCN(C)C)C(OC)=CC=C1NC(=O)C1=CC=C(C=2C(=CC(=CC=2)C=2N=C(C)ON=2)C)C=C1 JPBMDMNORXKGHZ-UHFFFAOYSA-N 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
• 229910000160 potassium phosphate Inorganic materials 0.000 description 3
• 235000011009 potassium phosphates Nutrition 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 238000010992 reflux Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 3
• ZQWCFDXBPRBYRO-UHFFFAOYSA-N 2-(2-bromo-5-nitrophenoxy)-n,n-dimethylethanamine Chemical compound CN(C)CCOC1=CC([N+]([O-])=O)=CC=C1Br ZQWCFDXBPRBYRO-UHFFFAOYSA-N 0.000 description 2
• HMOKSVVKKOQUMP-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]-4-nitrobenzonitrile Chemical compound [N+](=O)([O-])C1=CC(=C(C#N)C=C1)OCCN(C)C HMOKSVVKKOQUMP-UHFFFAOYSA-N 0.000 description 2
• UPUMETVQYQSNGW-UHFFFAOYSA-N 2-amino-4-chloropyrimidine-5-carbonitrile Chemical compound NC1=NC=C(C#N)C(Cl)=N1 UPUMETVQYQSNGW-UHFFFAOYSA-N 0.000 description 2
• IDGZUFFQKAIBOP-UHFFFAOYSA-N 2-aminoethyl methanesulfonate Chemical compound CS(=O)(=O)OCCN IDGZUFFQKAIBOP-UHFFFAOYSA-N 0.000 description 2
• ZAGAUUVCYGSPBP-UHFFFAOYSA-N 3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide Chemical compound C1=C(O)C(CCCN(C)C)=CC(C(=O)NC=2C=CC(=CC=2)C=2C=CN=CC=2)=C1 ZAGAUUVCYGSPBP-UHFFFAOYSA-N 0.000 description 2
• UOHJTNZWBOXTDY-UHFFFAOYSA-N 4-amino-3-bromo-N'-hydroxybenzenecarboximidamide Chemical compound NC(=NO)c1ccc(N)c(Br)c1 UOHJTNZWBOXTDY-UHFFFAOYSA-N 0.000 description 2
• OREVCMGFYSUYPX-UHFFFAOYSA-N 4-amino-3-chlorobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1Cl OREVCMGFYSUYPX-UHFFFAOYSA-N 0.000 description 2
• ODVFCHGIUDBMQB-UHFFFAOYSA-N 4-amino-3-cyclopropylbenzonitrile Chemical compound NC1=CC=C(C#N)C=C1C1CC1 ODVFCHGIUDBMQB-UHFFFAOYSA-N 0.000 description 2
• MNKUROPTDSZBPL-UHFFFAOYSA-N 4-bromo-3-[2-(dimethylamino)ethoxy]benzoic acid Chemical compound CN(C)CCOc1cc(ccc1Br)C(O)=O MNKUROPTDSZBPL-UHFFFAOYSA-N 0.000 description 2
• YWTKUWXYQQZSIL-UHFFFAOYSA-N 4-bromo-3-chlorobenzonitrile Chemical compound ClC1=CC(C#N)=CC=C1Br YWTKUWXYQQZSIL-UHFFFAOYSA-N 0.000 description 2
• IAFPKXUHZCNLHW-UHFFFAOYSA-N 4-bromo-3-cyclopropylbenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1C1CC1 IAFPKXUHZCNLHW-UHFFFAOYSA-N 0.000 description 2
• XQMUWERQTRJLKZ-UHFFFAOYSA-N 4-bromo-3-fluoro-N'-hydroxybenzenecarboximidamide Chemical compound O/N=C(/N)C1=CC=C(Br)C(F)=C1 XQMUWERQTRJLKZ-UHFFFAOYSA-N 0.000 description 2
• LXYOKQRGUOKFOV-UHFFFAOYSA-N 4-bromo-n'-hydroxy-3-methoxybenzenecarboximidamide Chemical compound COC1=CC(C(\N)=N\O)=CC=C1Br LXYOKQRGUOKFOV-UHFFFAOYSA-N 0.000 description 2
• DBGFGNCFYUNXLD-UHFFFAOYSA-N 4-chloropyrimidin-2-amine Chemical compound NC1=NC=CC(Cl)=N1 DBGFGNCFYUNXLD-UHFFFAOYSA-N 0.000 description 2
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
• WCCFLOQQACDOAX-UHFFFAOYSA-N 4-fluoropyridin-2-amine Chemical compound NC1=CC(F)=CC=N1 WCCFLOQQACDOAX-UHFFFAOYSA-N 0.000 description 2
• 102000035038 5-HT1 receptors Human genes 0.000 description 2
• 108091005478 5-HT1 receptors Proteins 0.000 description 2
• ZJUQAVKYHSQVEH-UHFFFAOYSA-N 5-bromo-4-[2-(dimethylamino)ethoxy]pyrimidin-2-amine Chemical compound CN(C)CCOC1=NC(N)=NC=C1Br ZJUQAVKYHSQVEH-UHFFFAOYSA-N 0.000 description 2
• 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 2
• GBKZCKNJGIKMGP-UHFFFAOYSA-N 6-amino-4-fluoropyridine-3-carbonitrile Chemical compound Nc1cc(F)c(cn1)C#N GBKZCKNJGIKMGP-UHFFFAOYSA-N 0.000 description 2
• BCOJWGIXSPPNSA-UHFFFAOYSA-N 6-fluoro-5-iodopyridin-2-amine Chemical compound NC1=CC=C(I)C(F)=N1 BCOJWGIXSPPNSA-UHFFFAOYSA-N 0.000 description 2
• UZALKVXCOUSWSL-UHFFFAOYSA-N 6-fluoropyridin-2-amine Chemical compound NC1=CC=CC(F)=N1 UZALKVXCOUSWSL-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• 102000007527 Autoreceptors Human genes 0.000 description 2
• 108010071131 Autoreceptors Proteins 0.000 description 2
• WSNCTWVUEBIAFB-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Br)=C2N)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Br)=C2N)=NO1 WSNCTWVUEBIAFB-UHFFFAOYSA-N 0.000 description 2
• ZGRUTSDYTIQIAA-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2Br)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2Br)=NO1 ZGRUTSDYTIQIAA-UHFFFAOYSA-N 0.000 description 2
• ZPOAYBDNRVVMQU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2N)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2N)=NO1 ZPOAYBDNRVVMQU-UHFFFAOYSA-N 0.000 description 2
• XXXKNNZNGOWLDU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2Br)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2Br)=NO1 XXXKNNZNGOWLDU-UHFFFAOYSA-N 0.000 description 2
• ITLISOYFTBPZLJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 ITLISOYFTBPZLJ-UHFFFAOYSA-N 0.000 description 2
• SJSQHUBBFOTCDH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(NC(C=C2)=NC(OCCN(C)C)=C2C#N)=O)=NO1 SJSQHUBBFOTCDH-UHFFFAOYSA-N 0.000 description 2
• KJAVMDBKCBQWBQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(O)=O)=NO1 KJAVMDBKCBQWBQ-UHFFFAOYSA-N 0.000 description 2
• PQSICVVNJPKJIX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(OC)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(C=C2)=NC=C2C(OC)=O)=NO1 PQSICVVNJPKJIX-UHFFFAOYSA-N 0.000 description 2
• SIZQFBFGUQIKHQ-UHFFFAOYSA-N CCOC(C1=CN=C(C(C=C2)=C(C3CC3)C=C2C2=NOC(C)=N2)N=C1)=O Chemical compound CCOC(C1=CN=C(C(C=C2)=C(C3CC3)C=C2C2=NOC(C)=N2)N=C1)=O SIZQFBFGUQIKHQ-UHFFFAOYSA-N 0.000 description 2
• CLKQBEBQPYWNFA-UHFFFAOYSA-N CN(C)CCOC(C=C(C=C1)C(OC)=O)=C1C#N Chemical compound CN(C)CCOC(C=C(C=C1)C(OC)=O)=C1C#N CLKQBEBQPYWNFA-UHFFFAOYSA-N 0.000 description 2
• 206010012335 Dependence Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 101150104779 HTR2A gene Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 101150036847 NOX1 gene Proteins 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
• 239000012979 RPMI medium Substances 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 238000006069 Suzuki reaction reaction Methods 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000016571 aggressive behavior Effects 0.000 description 2
• 230000001668 ameliorated effect Effects 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 239000000164 antipsychotic agent Substances 0.000 description 2
• 230000036506 anxiety Effects 0.000 description 2
• 150000008430 aromatic amides Chemical class 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 210000000748 cardiovascular system Anatomy 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000011712 cell development Effects 0.000 description 2
• 238000003570 cell viability assay Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 150000001805 chlorine compounds Chemical class 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 230000006806 disease prevention Effects 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 238000007876 drug discovery Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 230000026030 halogenation Effects 0.000 description 2
• 238000005658 halogenation reaction Methods 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 238000000126 in silico method Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000007477 logistic regression Methods 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• BBDHSRTWKZMNBH-UHFFFAOYSA-N methyl 4-bromo-3-[2-(dimethylamino)ethoxy]benzoate Chemical compound COC(=O)C1=CC=C(Br)C(OCCN(C)C)=C1 BBDHSRTWKZMNBH-UHFFFAOYSA-N 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• 210000001147 pulmonary artery Anatomy 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 201000000980 schizophrenia Diseases 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 230000007863 steatosis Effects 0.000 description 2
• 231100000240 steatosis hepatitis Toxicity 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 229910021653 sulphate ion Inorganic materials 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 231100000747 viability assay Toxicity 0.000 description 2
• 238000003026 viability measurement method Methods 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
• KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
• ABFQGXBZQWZNKI-UHFFFAOYSA-N 1,1-dimethoxyethanol Chemical compound COC(C)(O)OC ABFQGXBZQWZNKI-UHFFFAOYSA-N 0.000 description 1
• 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
• 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• KMHSUNDEGHRBNV-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=C(C#N)C(Cl)=N1 KMHSUNDEGHRBNV-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• KNJNITQHVLIWBN-UHFFFAOYSA-N 2-bromo-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1Br KNJNITQHVLIWBN-UHFFFAOYSA-N 0.000 description 1
• BUMGQSCPTLELLS-UHFFFAOYSA-N 2-chloro-5-nitrophenol Chemical compound OC1=CC([N+]([O-])=O)=CC=C1Cl BUMGQSCPTLELLS-UHFFFAOYSA-N 0.000 description 1
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
• DZNPHVPBCNZVGW-UHFFFAOYSA-N 2-hydroxy-4-nitrobenzonitrile Chemical compound OC1=CC([N+]([O-])=O)=CC=C1C#N DZNPHVPBCNZVGW-UHFFFAOYSA-N 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• 125000005916 2-methylpentyl group Chemical group 0.000 description 1
• GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical class NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005917 3-methylpentyl group Chemical group 0.000 description 1
• GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
• YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
• KSXUIQQDHHFSRN-UHFFFAOYSA-N 4-bromo-3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC(C#N)=CC=C1Br KSXUIQQDHHFSRN-UHFFFAOYSA-N 0.000 description 1
• HDWZDUKSIIRSCW-UHFFFAOYSA-N 4-bromo-3-chloro-N'-hydroxybenzenecarboximidamide Chemical compound N\C(=N\O)c1ccc(Br)c(Cl)c1 HDWZDUKSIIRSCW-UHFFFAOYSA-N 0.000 description 1
• QBKXYSXQKRNVRQ-UHFFFAOYSA-N 4-bromo-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1Br QBKXYSXQKRNVRQ-UHFFFAOYSA-N 0.000 description 1
• TWBFZKKJFREYES-UHFFFAOYSA-N 4-bromo-3-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC=C1Br TWBFZKKJFREYES-UHFFFAOYSA-N 0.000 description 1
• HBYSWPGIFNXVFX-UHFFFAOYSA-N 4-bromo-N'-hydroxy-3-(trifluoromethyl)benzenecarboximidamide Chemical compound BrC1=C(C=C(C(N)=NO)C=C1)C(F)(F)F HBYSWPGIFNXVFX-UHFFFAOYSA-N 0.000 description 1
• SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 1
• JOVLWUPTDOJTAI-UHFFFAOYSA-N 4-chloro-3-[2-(dimethylamino)ethoxy]aniline Chemical compound CN(C)CCOC1=CC(N)=CC=C1Cl JOVLWUPTDOJTAI-UHFFFAOYSA-N 0.000 description 1
• KCXIFTFXSFQXPW-UHFFFAOYSA-N 4-chloro-5-iodopyrimidin-2-amine Chemical compound NC1=NC=C(I)C(Cl)=N1 KCXIFTFXSFQXPW-UHFFFAOYSA-N 0.000 description 1
• LISISXJYGIZUEL-UHFFFAOYSA-N 4-fluoro-5-iodopyridin-2-amine Chemical compound NC1=CC(F)=C(I)C=N1 LISISXJYGIZUEL-UHFFFAOYSA-N 0.000 description 1
• UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
• 102000035037 5-HT3 receptors Human genes 0.000 description 1
• 108091005477 5-HT3 receptors Proteins 0.000 description 1
• ZNHIZVRENCRAPA-UHFFFAOYSA-N 5-bromo-4-chloropyrimidin-2-amine Chemical compound NC1=NC=C(Br)C(Cl)=N1 ZNHIZVRENCRAPA-UHFFFAOYSA-N 0.000 description 1
• GGHBRLQYBZMEPV-UHFFFAOYSA-N 5-bromo-4-fluoropyridin-2-amine Chemical compound NC1=CC(F)=C(Br)C=N1 GGHBRLQYBZMEPV-UHFFFAOYSA-N 0.000 description 1
• SJXWFNBZBXZDCL-UHFFFAOYSA-N 5-bromo-6-fluoropyridin-2-amine Chemical compound NC1=CC=C(Br)C(F)=N1 SJXWFNBZBXZDCL-UHFFFAOYSA-N 0.000 description 1
• 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
• 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 description 1
• 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
• 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
• JJGGPPOJXKTUQD-UHFFFAOYSA-N 6-amino-2-fluoropyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C(F)=N1 JJGGPPOJXKTUQD-UHFFFAOYSA-N 0.000 description 1
• PDXLDEANFZSJBD-UHFFFAOYSA-N 6-amino-4-[2-(dimethylamino)ethoxy]pyridine-3-carbonitrile Chemical compound CN(C)CCOc1cc(N)ncc1C#N PDXLDEANFZSJBD-UHFFFAOYSA-N 0.000 description 1
• XTHKRYHULUJQHN-UHFFFAOYSA-N 6-bromopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1 XTHKRYHULUJQHN-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
• 206010001488 Aggression Diseases 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• JHBZSBCWNOOVOC-UHFFFAOYSA-N CC1(C)OB(C(C=C2)=C(C(F)(F)F)C=C2C2=NOC(C)=N2)OC1(C)C Chemical compound CC1(C)OB(C(C=C2)=C(C(F)(F)F)C=C2C2=NOC(C)=N2)OC1(C)C JHBZSBCWNOOVOC-UHFFFAOYSA-N 0.000 description 1
• VLBNVGOQAJBCLE-UHFFFAOYSA-N CC1(C)OB(C(C=CC(C2=NOC(C)=N2)=C2)=C2Cl)OC1(C)C Chemical compound CC1(C)OB(C(C=CC(C2=NOC(C)=N2)=C2)=C2Cl)OC1(C)C VLBNVGOQAJBCLE-UHFFFAOYSA-N 0.000 description 1
• CWUMCIJMHQWRQS-UHFFFAOYSA-N CC1(C)OB(C(C=CC(C2=NOC(C)=N2)=C2)=C2F)OC1(C)C Chemical compound CC1(C)OB(C(C=CC(C2=NOC(C)=N2)=C2)=C2F)OC1(C)C CWUMCIJMHQWRQS-UHFFFAOYSA-N 0.000 description 1
• DRYFZSWSIBMJQZ-UHFFFAOYSA-N CC1(C)OB(C(C=CC(C2=NOC(C)=N2)=C2)=C2OC)OC1(C)C Chemical compound CC1(C)OB(C(C=CC(C2=NOC(C)=N2)=C2)=C2OC)OC1(C)C DRYFZSWSIBMJQZ-UHFFFAOYSA-N 0.000 description 1
• ILOWYRJESNGKPX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 ILOWYRJESNGKPX-UHFFFAOYSA-N 0.000 description 1
• PDKPOZOWGBTKFE-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 PDKPOZOWGBTKFE-UHFFFAOYSA-N 0.000 description 1
• DLQPALGVQHBTNN-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(NC(C=C2)=CC(OCCN(C)C)=C2C#N)=O)=NO1 DLQPALGVQHBTNN-UHFFFAOYSA-N 0.000 description 1
• KEWMNGMUDBBHKQ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(O)=O)=NO1 KEWMNGMUDBBHKQ-UHFFFAOYSA-N 0.000 description 1
• LXXYDFCEIHLJPC-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(OC)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C#N)=C2C(C=C2)=NC=C2C(OC)=O)=NO1 LXXYDFCEIHLJPC-UHFFFAOYSA-N 0.000 description 1
• KYORWDMUYZPDQV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 KYORWDMUYZPDQV-UHFFFAOYSA-N 0.000 description 1
• GDLZCAWFIUDORV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C(F)(F)F)=C2C(C=C2)=CC=C2C(O)=O)=NO1 GDLZCAWFIUDORV-UHFFFAOYSA-N 0.000 description 1
• WJBBHYVTUIGUEF-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(Cl)=O)=NO1 WJBBHYVTUIGUEF-UHFFFAOYSA-N 0.000 description 1
• BWXRUEFUKGZDKJ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(C3CC3)=C2C(N=C2)=NC=C2C(O)=O)=NO1 BWXRUEFUKGZDKJ-UHFFFAOYSA-N 0.000 description 1
• HRKLUYDHWLDGBZ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 HRKLUYDHWLDGBZ-UHFFFAOYSA-N 0.000 description 1
• XIYHMHOTWRQUSZ-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=CC=C2C(O)=O)=NO1 XIYHMHOTWRQUSZ-UHFFFAOYSA-N 0.000 description 1
• DUVLVXSBHPQQRG-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 DUVLVXSBHPQQRG-UHFFFAOYSA-N 0.000 description 1
• MPEPIKAAFOVJNH-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(Cl)=C2C(C=C2)=NC=C2C(O)=O)=NO1 MPEPIKAAFOVJNH-UHFFFAOYSA-N 0.000 description 1
• OMBICAMOOLENIY-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=CC=C2C(Cl)=O)=NO1 OMBICAMOOLENIY-UHFFFAOYSA-N 0.000 description 1
• LMLWAAABNMWQDU-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(Cl)=O)=NO1 LMLWAAABNMWQDU-UHFFFAOYSA-N 0.000 description 1
• HUCZYPBVTPYVIX-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(NC(C=C2OCCN(C)C)=NC=C2Br)=O)=NO1 HUCZYPBVTPYVIX-UHFFFAOYSA-N 0.000 description 1
• UXCTZARGPQAFDD-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(C=C2)=NC=C2C(O)=O)=NO1 UXCTZARGPQAFDD-UHFFFAOYSA-N 0.000 description 1
• GIHLFTVVMDCCJV-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2N)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(F)=C2C(N=C2)=CC=C2N)=NO1 GIHLFTVVMDCCJV-UHFFFAOYSA-N 0.000 description 1
• AKXSSGOVUHUQLF-UHFFFAOYSA-N CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(O)=O)=NO1 Chemical compound CC1=NC(C(C=C2)=CC(OC)=C2C(C=C2)=NC=C2C(O)=O)=NO1 AKXSSGOVUHUQLF-UHFFFAOYSA-N 0.000 description 1
• OPTZNUPNASZZJH-UHFFFAOYSA-N CN(C)CCOC(C=C(C=C1)C(O)=O)=C1C#N Chemical compound CN(C)CCOC(C=C(C=C1)C(O)=O)=C1C#N OPTZNUPNASZZJH-UHFFFAOYSA-N 0.000 description 1
• WIZACSFCKFAVRY-UHFFFAOYSA-N CN(C)CCOC1=NC(N)=NC=C1C#N Chemical compound CN(C)CCOC1=NC(N)=NC=C1C#N WIZACSFCKFAVRY-UHFFFAOYSA-N 0.000 description 1
• 101100048435 Caenorhabditis elegans unc-18 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 101710155322 Cys-loop ligand-gated ion channel Proteins 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004150 EU approved colour Substances 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 102000034354 Gi proteins Human genes 0.000 description 1
• 108091006101 Gi proteins Proteins 0.000 description 1
• 102000017911 HTR1A Human genes 0.000 description 1
• 101150004776 HTR1E gene Proteins 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019708 Hepatic steatosis Diseases 0.000 description 1
• 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
• 101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
• 101000872147 Homo sapiens Biogenesis of lysosome-related organelles complex 1 subunit 6 Proteins 0.000 description 1
• 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
• 101000693011 Homo sapiens Pancreatic alpha-amylase Proteins 0.000 description 1
• 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
• 101150039275 Htr1f gene Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• YZNBVSBSIQOQDC-UHFFFAOYSA-N N=C(C(C=C1)=CC(C#N)=C1Br)NO Chemical compound N=C(C(C=C1)=CC(C#N)=C1Br)NO YZNBVSBSIQOQDC-UHFFFAOYSA-N 0.000 description 1
• CROOXVWVZMSKFK-UHFFFAOYSA-N N=C(C(C=C1)=CC(C2CC2)=C1Br)NO Chemical compound N=C(C(C=C1)=CC(C2CC2)=C1Br)NO CROOXVWVZMSKFK-UHFFFAOYSA-N 0.000 description 1
• 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
• 102000004019 NADPH Oxidase 1 Human genes 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 102000005650 Notch Receptors Human genes 0.000 description 1
• 108010070047 Notch Receptors Proteins 0.000 description 1
• 230000005913 Notch signaling pathway Effects 0.000 description 1
• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 108060006706 SRC Proteins 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 101100321769 Takifugu rubripes htr1d gene Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 235000011114 ammonium hydroxide Nutrition 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 230000002460 anti-migrenic effect Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 230000004900 autophagic degradation Effects 0.000 description 1
• 230000007747 autophagy signaling pathway Effects 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000004641 brain development Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 230000023402 cell communication Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 230000037326 chronic stress Effects 0.000 description 1
• 230000027288 circadian rhythm Effects 0.000 description 1
• 230000003021 clonogenic effect Effects 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
• 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
• IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000000380 hallucinogen Substances 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000056984 human BLOC1S6 Human genes 0.000 description 1
• 102000055276 human IL3 Human genes 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 238000013160 medical therapy Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• VYOFPLOREOHCDP-UHFFFAOYSA-N methyl 4-bromo-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(Br)C(O)=C1 VYOFPLOREOHCDP-UHFFFAOYSA-N 0.000 description 1
• NFLROFLPSNZIAH-UHFFFAOYSA-N methyl 6-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Br)N=C1 NFLROFLPSNZIAH-UHFFFAOYSA-N 0.000 description 1
• 229960001186 methysergide Drugs 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000008747 mitogenic response Effects 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical compound NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
• LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000003414 procognitive effect Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940075993 receptor modulator Drugs 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 239000006190 sub-lingual tablet Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000007939 sustained release tablet Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 230000028016 temperature homeostasis Effects 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000001103 thalamus Anatomy 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 238000007738 vacuum evaporation Methods 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
• 239000002550 vasoactive agent Substances 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1